Merck, Hansoh Pharma in Obesity Pill License Potentially Worth More Than $2 Billion

Dow Jones2024-12-18

By Colin Kellaher

Merck & Co. is licensing a potential oral obesity drug from Hansoh Pharma in a deal potentially worth more than $2 billion to the Chinese biopharmaceutical company.

Merck on Wednesday said it will make an upfront payment of $112 million to Hansoh in exchange for an exclusive global license to HS-10535, an investigational small-molecule GLP-1 receptor agonist.

The Rahway, N.J., drugmaker said Hansoh also is eligible to receive up to $1.9 billion in milestone payments, along with royalties on product sales.

GLP-1 drugs, which work in part by mimicking a gut hormone to suppress appetite and make users feel full, are used to treat both Type 2 diabetes and obesity. These include the blockbuster injectable drugs Ozempic and Wegovy from Novo Nordisk and Mounjaro and Zepbound from Eli Lilly, and pharmaceutical companies are racing to break into the burgeoning sector with weight-loss pills.

Merck said it plans to evaluate HS-10535's potential to provide additional cardiometabolic benefits beyond weight loss.

The company said it will post a fourth-quarter charge of four cents a share related to the Hansoh deal.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

December 18, 2024 07:24 ET (12:24 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2492716907?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-18 20:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492716907","market":"fut","top_or_hot":-1,"title":"Merck, Hansoh Pharma in Obesity Pill License Potentially Worth More Than $2 Billion","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre>\n \n</pre>\n<p>\n  Merck &amp; Co. is licensing a potential oral obesity drug from Hansoh Pharma in a deal potentially worth more than $2 billion to the Chinese biopharmaceutical company. \n</p>\n<p>\n  Merck on Wednesday said it will make an upfront payment of $112 million to Hansoh in exchange for an exclusive global license to HS-10535, an investigational small-molecule GLP-1 receptor agonist. \n</p>\n<p>\n  The Rahway, N.J., drugmaker said Hansoh also is eligible to receive up to $1.9 billion in milestone payments, along with royalties on product sales. \n</p>\n<p>\n  GLP-1 drugs, which work in part by mimicking a gut hormone to suppress appetite and make users feel full, are used to treat both Type 2 diabetes and obesity. These include the blockbuster injectable drugs Ozempic and Wegovy from Novo Nordisk and Mounjaro and Zepbound from Eli Lilly, and pharmaceutical companies are racing to break into the burgeoning sector with weight-loss pills. \n</p>\n<p>\n  Merck said it plans to evaluate HS-10535's potential to provide additional cardiometabolic benefits beyond weight loss. \n</p>\n<p>\n  The company said it will post a fourth-quarter charge of four cents a share related to the Hansoh deal. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 18, 2024 07:24 ET (12:24 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck, Hansoh Pharma in Obesity Pill License Potentially Worth More Than $2 Billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck, Hansoh Pharma in Obesity Pill License Potentially Worth More Than $2 Billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-18 20:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Colin Kellaher \n\n\n \n\n\n  Merck & Co. is licensing a potential oral obesity drug from Hansoh Pharma in a deal potentially worth more than $2 billion to the Chinese biopharmaceutical company. \n\n\n  ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2492716907","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492716907","pubTimestamp":1734524640,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Merck & Co. is licensing a potential oral obesity drug from Hansoh Pharma in a deal potentially worth more than $2 billion to the Chinese biopharmaceutical company.Merck on Wednesday said it will make an upfront payment of $112 million to Hansoh in exchange for an exclusive global license to HS-10535, an investigational small-molecule GLP-1 receptor agonist.The Rahway, N.J., drugmaker said Hansoh also is eligible to receive up to $1.9 billion in milestone payments, along with royalties on product sales.GLP-1 drugs, which work in part by mimicking a gut hormone to suppress appetite and make users feel full, are used to treat both Type 2 diabetes and obesity. These include the blockbuster injectable drugs Ozempic and Wegovy from Novo Nordisk and Mounjaro and Zepbound from Eli Lilly, and pharmaceutical companies are racing to break into the burgeoning sector with weight-loss pills.Merck said it plans to evaluate HS-10535's potential to provide additional cardiometabolic benefits beyond we","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"默克(Merck)和豪森制药(Hansoh Pharma)获得减肥药许可，价值可能超过20亿美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRK":1,"03692":0.9},"content_text":"By Colin Kellaher \n\n\n \n\n\n  Merck & Co. is licensing a potential oral obesity drug from Hansoh Pharma in a deal potentially worth more than $2 billion to the Chinese biopharmaceutical company. \n\n\n  Merck on Wednesday said it will make an upfront payment of $112 million to Hansoh in exchange for an exclusive global license to HS-10535, an investigational small-molecule GLP-1 receptor agonist. \n\n\n  The Rahway, N.J., drugmaker said Hansoh also is eligible to receive up to $1.9 billion in milestone payments, along with royalties on product sales. \n\n\n  GLP-1 drugs, which work in part by mimicking a gut hormone to suppress appetite and make users feel full, are used to treat both Type 2 diabetes and obesity. These include the blockbuster injectable drugs Ozempic and Wegovy from Novo Nordisk and Mounjaro and Zepbound from Eli Lilly, and pharmaceutical companies are racing to break into the burgeoning sector with weight-loss pills. \n\n\n  Merck said it plans to evaluate HS-10535's potential to provide additional cardiometabolic benefits beyond weight loss. \n\n\n  The company said it will post a fourth-quarter charge of four cents a share related to the Hansoh deal. \n\n\n \n\n\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 18, 2024 07:24 ET (12:24 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492716907"}